News >

Pembrolizumab Plus Olaparib Shows Potential in Heavily Pretreated mCRPC

Brandon Scalea
Published: Monday, Jun 24, 2019

Evan Ya-Wen Yu, MD, a professor in the Department of Medical Oncology, University of Washington School of Medicine, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance

Evan Ya-Wen Yu, MD

Although the combination of pembrolizumab (Keytruda) and olaparib (Lynparza) induced modest response rates in molecularly unselected patients with metastatic castration-resistant prostate cancer (mCRPC), the activity in this heavily pretreated population is encouraging, said Evan Y. Yu, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x